DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix - PubMed
3 months ago
- #Clinical Trial
- #Gynecologic Cancers
- #Immunotherapy
- DART/SWOG/NCI phase II trial evaluates ipilimumab-nivolumab immunotherapy in gynecologic clear cell carcinomas (CCCs).
- The trial included 32 patients with ovarian, endometrial, and cervical CCCs, with an overall response rate (ORR) of 9.38%.
- Two complete responses (CRs) were observed in ovarian CCC patients, ongoing for over 3 years.
- ORR increased to 12.5% when including a partial response (PR) by iRECIST criteria in a cervical CCC patient.
- Clinical benefit rate (CBR) was 21.88%, with durable responses in some patients.
- Median overall survival (OS) was 21.7 months for all evaluable patients.
- Safety profile was consistent with known effects of ipilimumab and nivolumab, with no treatment-related deaths.
- Correlative studies are ongoing to identify patients likely to respond to this combination therapy.